바이오엔테크 임상시험

바이오엔테크이(가) 진행한 임상시험의 단계, 대상 질환, 공개된 결과를 정리했습니다.

• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects Wi
  1/2상 · Non-CNS Tumor · 조기 종료 · 2026년 7월 2일
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in
  3상 · SARS-CoV-2 Infection, COVID-19 · 완료 · 2026년 5월 28일
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
  2/3상 · SARS-CoV-2 Infection · 완료 · 2026년 4월 28일
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COV
  2/3상 · SARS-CoV-2 Infection · 완료 · 2026년 3월 25일
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizuma
  2상 · Advanced Melanoma · 완료 · 2026년 1월 30일
• Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
  1상 · SARS-CoV-2 Infection · 완료 · 2026년 1월 13일
• A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi
  2상 · Melanoma Stage III · 완료 · 2025년 12월 15일
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate
  3상 · Influenza · 완료 · 2025년 12월 4일
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVI
  3상 · SARS-CoV-2 Infection · 완료 · 2025년 11월 10일
• Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in
  1/2상 · Pancreatic Cancer · 조기 종료 · 2025년 10월 31일
• A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
  2/3상 · SARS-CoV-2 Infection · 완료 · 2025년 10월 1일
• Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
  1상 · Malaria · 완료 · 2025년 9월 3일
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates A
  2상 · Influenza, Human · 완료 · 2025년 7월 23일
• BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
  1/2상 · Solid Tumor · 조기 종료 · 2025년 7월 2일
• A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tu
  1/2상 · Solid Tumor, Adult · 조기 종료 · 2025년 4월 22일

기업별 임상

화이자머크(MSD)로슈노바티스아스트라제네카존슨앤드존슨(얀센)BMS사노피GSK일라이 릴리애브비암젠바이엘베링거인겔하임노보 노디스크다케다길리어드모더나바이오엔테크리제네론버텍스바이오젠다이이찌산쿄아스텔라스에자이오츠카세르비에인사이트셀트리온삼성바이오에피스한미약품유한양행

전체 임상